Head-To-Head Comparison: Achaogen (NASDAQ:AKAO) and CELYAD SA/ADR (NASDAQ:CYAD)

Achaogen (NASDAQ:AKAO) and CELYAD SA/ADR (NASDAQ:CYAD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.


This table compares Achaogen and CELYAD SA/ADR’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Achaogen -2,136.94% -357.49% -127.68%

Risk and Volatility

Achaogen has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, CELYAD SA/ADR has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.

Institutional and Insider Ownership

31.9% of Achaogen shares are held by institutional investors. Comparatively, 7.3% of CELYAD SA/ADR shares are held by institutional investors. 7.8% of Achaogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Achaogen and CELYAD SA/ADR’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Achaogen $8.73 million 0.00 -$186.51 million ($3.70) N/A
CELYAD SA/ADR $3.68 million 37.82 -$44.20 million ($3.97) -3.55

CELYAD SA/ADR has lower revenue, but higher earnings than Achaogen. CELYAD SA/ADR is trading at a lower price-to-earnings ratio than Achaogen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Achaogen and CELYAD SA/ADR, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Achaogen 0 8 0 0 2.00
CELYAD SA/ADR 0 0 3 0 3.00

Achaogen presently has a consensus target price of $6.60, suggesting a potential upside of ∞. CELYAD SA/ADR has a consensus target price of $36.50, suggesting a potential upside of 158.87%. Given Achaogen’s higher probable upside, research analysts plainly believe Achaogen is more favorable than CELYAD SA/ADR.


CELYAD SA/ADR beats Achaogen on 7 of the 13 factors compared between the two stocks.

About Achaogen

Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.


Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.